BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 16489002)

  • 21. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway.
    Woo JK; Choi Y; Oh SH; Jeong JH; Choi DH; Seo HS; Kim CW
    Oncogene; 2012 Apr; 31(17):2187-98. PubMed ID: 21927028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
    Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
    Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M; Yao J; Yu D
    Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.
    Zetser A; Bashenko Y; Edovitsky E; Levy-Adam F; Vlodavsky I; Ilan N
    Cancer Res; 2006 Feb; 66(3):1455-63. PubMed ID: 16452201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTHrP regulates angiogenesis and bone resorption via VEGF expression.
    Isowa S; Shimo T; Ibaragi S; Kurio N; Okui T; Matsubara K; Hassan NM; Kishimoto K; Sasaki A
    Anticancer Res; 2010 Jul; 30(7):2755-67. PubMed ID: 20683010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.
    Nör JE; Christensen J; Liu J; Peters M; Mooney DJ; Strieter RM; Polverini PJ
    Cancer Res; 2001 Mar; 61(5):2183-8. PubMed ID: 11280784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose.
    Jiang W; Zhu Z; Thompson HJ
    Mol Carcinog; 2008 Aug; 47(8):616-28. PubMed ID: 18247380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
    Frost P; Shi Y; Hoang B; Lichtenstein A
    Oncogene; 2007 Apr; 26(16):2255-62. PubMed ID: 17016437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
    Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
    Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1.
    Tornillo G; Bisaro B; Camacho-Leal Mdel P; Galiè M; Provero P; Di Stefano P; Turco E; Defilippi P; Cabodi S
    Eur J Cell Biol; 2011; 90(2-3):237-48. PubMed ID: 20961652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.
    Narita K; Staub J; Chien J; Meyer K; Bauer M; Friedl A; Ramakrishnan S; Shridhar V
    Cancer Res; 2006 Jun; 66(12):6025-32. PubMed ID: 16778174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.
    Yang W; Klos K; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2002 Jun; 94(11):2855-61. PubMed ID: 12115372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy.
    Chelouche-Lev D; Miller CP; Tellez C; Ruiz M; Bar-Eli M; Price JE
    Eur J Cancer; 2004 Nov; 40(16):2509-18. PubMed ID: 15519527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
    Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
    Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
    Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
    Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
    Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P; Mateo J
    Oncogene; 2009 Jan; 28(3):313-24. PubMed ID: 18978810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.